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This study was conducted to identify the characteristic pharmacological features of GT-0198 that is
phenoxymethylbenzamide derivatives. GT-0198 inhibited the function of glycine transporter 2 (GlyT2) in
human GlyT2-expressing HEK293 cells and did not bind various major transporters or receptors of
neurotransmitters in a competitive manner. Thus, GT-0198 is considered to be a comparatively selective
GlyT2 inhibitor. Intravenous, oral, and intrathecal injections of GT-0198 decreased the pain-related
response in a model of neuropathic pain with partial sciatic nerve ligation. This result suggests that
GT-0198 has an analgesic effect. The analgesic effect of GT-0198 was abolished by the intrathecal in-
jection of strychnine, a glycine receptor antagonist. Therefore, GT-0198 is considered to exhibit its
analgesic effect via the activation of a glycine receptor by glycine following presynaptic GlyT2 inhibition
in the spinal cord. In summary, GT-0198 is a structurally novel GlyT2 inhibitor bearing a phenox-
ymethylbenzamide moiety with in vivo efﬁcacy in behavioral models of neuropathic pain.
© 2015 Toray Industries, Inc. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glycine acts as an inhibitory neurotransmitter on the
strychnine-sensitive glycine receptors (1), which are abundant in
the spinal dorsal horn (2e4). In an animal model of neuropathic
pain, chronic and single intrathecal administration of glycine sup-
pressed mechanical hyperalgesia (5) and thermal hyperalgesia (6),
respectively. These ﬁndings suggest that dysfunction of inhibitory
synaptic transmission by glycine in the spinal dorsal horn is
involved in the development of neuropathic pain (7). In fact, the
glycine receptor antagonist strychnine elicits mechanical allodynia
that is caused by glycinergic disinhibition in the spinal dorsal horn
(8, 9). Thus, an enhancement of glycinergic inhibition in the spinal
dorsal horn is a potential strategy for the relief of neuropathic pain.
The extracellular concentration of glycine is regulated by its
reuptake into glycinergic presynaptic terminals and uptake into
glial cells adjacent to inhibitory and excitatory synapses via Naþ/
Cl-dependent glycine transporters (GlyTs) (10). TwoGlyT subtypes
encoded by distinct genes, GlyT1 and GlyT2, have been identiﬁed inþ81 467 329862.
ri).
rmacological Society.
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y-nc-nd/4.0/).the mammalian central nervous system (1, 11). Recent studies have
demonstrated that intrathecal injections of GlyT1 and GlyT2 in-
hibitors produce analgesic effects in animal models of neuropathic
and inﬂammatory pain (12e14). The GlyT2 subtype is expressed in
presynaptic glycinergic neurons of the spinal cord. Based on this
localization, GlyT2 is believed to contribute to the clearance of
glycine from the synapse at inhibitory synapses. On the other hand,
GlyT1 is expressed in glial cells surrounding not only glycinergic
but also glutaminergic synapses (1, 15). Therefore, GlyT1 inhibitor
increases glycine concentrations at the glutaminergic terminal and
may activate glutamate receptors, speciﬁcally N-methyl-D-aspar-
tate (NMDA) receptors, given that glycine has been identiﬁed as a
required coagonist with glutamate for NMDA receptors. Once an
NMDA receptor is activated by the GlyT1 inhibitor, excitatory syn-
aptic transmission is enhanced. These results indicate that a GlyT1
inhibitor has 2 effects: analgesic and algesic. Thus, GlyT2 inhibitors
may be more useful than GlyT1 inhibitors as analgesic drugs.
Recently, we explored the structurally novel GlyT2 inhibitor by
structural modiﬁcations of phenoxybenzamide derivative and we
successfully designed GT-0198 that has strong potency of inhibition
of GlyT2 (Fig.1). Furthermore, GT-0198 showed the good in vivo
pharmacokinetics parameters (Table 1). Therefore, GT-0198 is ex-
pected to become a therapeutic agent of neuropathic pain by oral
administration as tablets or capsules. In the present study, we showof Japanese Pharmacological Society. This is an open access article under the CC BY-
Fig. 1. The chemical structure of GT-0198.
Table 2
Effect of GT-0198 on Radioligand binding to various transporters and receptors of
neurotransmitters.
Target Species Inhibition (%)
GT-0198 Positive substance
Adenosine transporter Human 4.24 100.00 (NBTI)
Monoamine transporter Human 1.02 99.78 (Ketanserin)
Norepinephrine transporter Human 11.02 100.00 (Desipramine)
Dopamine transporter Human 23.16 99.70 (GBR12909)
GABA transporter Rat 0.49 97.61 (GABA)
Serotonin transporter Human 20.05 100.00 (Imipramine)
GABA A (Agonist site) Rat 0.00 99.80 (Muscimol)
GABA A (BZ central) Rat 0.02 100.00 (Diazepam)
GABA A (Chloride channel) Rat 0.00 96.23 (Picrotoxin)
GABA B Rat 2.00 100.00 (GABA)
Y. Omori et al. / Journal of Pharmacological Sciences 127 (2015) 377e381378the analgesic effect of GT-0198 in an animal model of neuropathic
pain.
2. Materials and methods
2.1. Animals
Male ICR mice (5 weeks old at the start of experiments; Japan
SLC Inc., Shizuoka, Japan) were used. All mice were housed 3e5
animals per cage under a room temperature of 21Ce25 C, hu-
midity of 40%e70%, and 12-h light/dark cycle (light on at 7:00 AM)
for at least 1 week before use. Mice had ad libitum access to food
and water. All experiments were conducted according to the
Guidelines for Animal Experiments, Research & Development Di-
vision, Toray Industries, Inc., and a pain test was performed ac-
cording to the Guidelines on Ethical Standards for Investigation of
Experimental Pain in Animals (16).
2.2. Surgical operation
The mice were anesthetized with sodium pentobarbital (70 mg/
kg, i.p.). We produced a partial sciatic nerve ligation (PSNL) model
by tying a tight ligature with an 8e0 silk suture around approxi-
mately one-third to one-half the diameter of the sciatic nerve on
the right side as described previously (17, 18). The sham-operated
group was subjected to all procedures except ligation. In the pre-
sent study, the pain test was performed 7 days after nerve ligation.
2.3. Pain test
To evaluate the analgesic effect of the compounds, paw with-
drawal responses were measured using a von Frey ﬁlament (North
Coast Medical, Morgan Hill, CA, USA) with a bending force of 0.16 g.
The mice were placed individually in acrylic cages with wire mesh
bottoms. After at least 60 min of acclimation, the von Frey ﬁlament
was applied to the plantar surface of the hind paws for 3 s, and this
was repeated 3 times. Each hind paw of the mice was tested indi-
vidually. Paw withdrawal response to the von Frey ﬁlament was
evaluated by scoring as follows: 0, no response; 1, slow and/or
slight response to the stimulus; 2, quick withdrawal response away
from the stimulus without ﬂinching or licking; 3, intense with-
drawal response away from the stimulus with brisk ﬂinching and/
or licking. The sum of 3 values served as the pain-related score.Table 1
Pharmacokinetic parameters (brain and plasma ratio) of GT-0198
after oral administration (10 mg/kg).
Brain concentration (ng/g) 4478
Plasma concentration (ng/g) 300
Brain/Plasma ratio (%) 16.7
Blood and brain samples were collected at 1 h. Blood samples were
centrifuged at 3000 g for 10 min and stored at 20 C until analysis.
Brain samples were homogenized and stored at 80 C until
analysis.2.4. Glycine uptake assays with GlyT1 and GlyT2 transfected human
embryonic kidney 293 cells
A vector expressing human GlyT1 or GlyT2 (GeneCopoeia, Inc.
Rockville, MD, USA) was transfected into human embryonic kidney
293 (HEK 293) cells using Lipofectamine 2000 (Life Technologies
Corporation, Carlsbad, CA, USA). The transfected HEK293 cells were
cultured in Dulbecco's Modiﬁed Eagle's Medium (DMEM) supple-
mented with 10% fetal bovine serum. Stable single-cell clones for
hGlyT1 or hGlyT2 were isolated by selection with 500 mg/mL
geneticin. Selected clones were evaluated in [3H]-glycine uptake
assays. HEK293 cells were plated (6000 cells per well) in polylysine-
coated 96-well CytoStar-T®plates (Perkinelmer,Waltham,MA, USA)
and incubated overnight. The cells were then incubated at 37 C for
2 h with 240 nM [3H]-glycine together with any compound being
evaluated, in a total volume of 0.5 mL. At the end of the incubation,
the radioactivity content of the wells was measured using Packard
TopCount (Perkinelmer, Waltham, MA, USA).
2.5. Binding assays to various transporters and receptors of
neurotransmitters
To evaluate the afﬁnity of GT-0198 for various transporters and
receptors, the rate of inhibition of the binding of a speciﬁc ligand to
each transporter or receptor was assayed, as shown in Table 2. These
assays were carried out in Sekisui Medical co., Ltd. Test substance
concentration is 10 mM and positive substance concentration is 1 or
10 mM. Data are expressed as the mean values of duplicate samples.
The inhibition ratios were calculated from “100 e binding ratio”.
Binding ratio:
(Bound radioactivity in the presence of the test substancee Non-
speciﬁcbound radioactivity)/(Totalbound radioactivity in theabsence
of the test substance e Non-speciﬁc bound radioactivity) 100 (%)
2.6. Drugs
GT-0198was synthesized by Toray Industries Inc. Pregabalinwas
obtained from Bosch Scientiﬁc (New Brunswick, NJ, USA) and
strychnine was obtained from Sigma (St. Louis, MO, USA). ForGlutamate (AMPA) Rat 2.29 100.00 ((S)-AMPA)
Glutamate (Kainate) Rat 0.00 100.00 (Kainic acid)
Glutamate (NMDA agonist site) Rat 1.71 99.23 (L-Glutamic acid)
Glutamate (NMDA glycine site) Rat 0.00 99.49 (MDL105,519)
Glutamate (NMDA
Phencyclidine site)
Rat 6.48 100.00 ((þ)-MK-801)
Glutamate (NMDA polyamine site) Rat 11.89 99.85 (Ifenprodil)
Glycine (Strychnine sensitive) Rat 24.26 100.00 (Strychnine)
The concentration of GT-0198 is 1 mM. Data are expressed as the mean values of
duplicate samples.
GABA ¼ gamma-aminobutyric acid; NMDA ¼ N-methyl-D-aspartate; AMPA ¼ a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; PCP ¼ phencyclidine,
NBTI ¼ S-(4-Nitrobenzyl)-6-thioinosine.
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Fig. 3. Effects of GT-0198 on pain-related behavioral responses to mechanical stimuli
in mice with partial sciatic nerve ligation. GT-0198, pregabalin, and vehicle were
injected intravenously (A) and orally (B) 7 days after nerve ligation. The hind paws
were stimulated using a von Frey ﬁlament with a bending force of 0.16 g. The values
represent the mean and S.E.M. of 4e6 animals. *P < 0.05 vs. vehicle-injection (Two-
way ANOVA).
Y. Omori et al. / Journal of Pharmacological Sciences 127 (2015) 377e381 379intravenous or intrathecal injection, the compoundswere dissolved
in saline and injected in a volume of 0.1 mL/10 g body weight
(intravenously) or 5 mL/body (intrathecally). For oral administra-
tion, the compounds were dissolved in distilled water and injected
in a volume of 0.1 mL/10 g body weight.
2.7. Data analysis
Data are expressed asmean ± S.E.M. Difference among group for
analgesic effects was determined using two-way analysis of vari-
ance (ANOVA) followed by suitable post-hoc test. P < 0.05 was
considered to be signiﬁcant.
3. Results
3.1. Inhibition of GlyT2 by GT-0198
GT-0198 inhibited the function of GlyT2 in human GlyT2-
expressing HEK293 cells, with an IC50 value of 105 nM (Fig. 2). In
contrast, GT-0198 did not suppress the function of GlyT1 (Fig. 2).
Moreover, GT-0198 did not bind major transporters or receptors of
neurotransmitters in the spinal cord in a competitive manner
(Table 2). We accordingly inferred that GT-0198 is a compound that
inhibits GlyT2 without inhibition of major transporters and re-
ceptors of neurotransmitters in the spinal cord.
3.1.1. Analgesic effects of systemic injection of GT-0198 on
withdrawal responses in animal models of neuropathic pain
The effect of GT-0198 and pregabalin on withdrawal responses
to mechanical stimuli was investigated in PSNL model mice (Fig.3).
The model mice showed increased pain-related scores compared
with sham-operated mice. Intravenous injection of GT-0198
decreased the pain-related score (Fig. 3A). Oral injection of GT-
0198 also reduced the score in a dose-related manner, with sta-
tistical signiﬁcance at 10 mg/kg (Fig. 3B). Pregabalin also signiﬁ-
cantly decreased the pain-related score at a dose of 10 mg/kg. In
these experiments with GT-0198, no side effects possibly caused by
glycine, such as convulsions or tremors, were observed.
3.1.2. Effect of intrathecal injection of GT-0198 on withdrawal
responses in animal models of neuropathic pain
Because GlyT2 is abundant in the spinal dorsal horn, the anal-
gesic effect of intrathecally injected GT-0198 was investigated in a
mouse model of neuropathic pain. Intrathecal injection of GT-0198
decreased the pain-related score in a dose-related manner, with
statistical signiﬁcance at 1 mg/site (Fig. 4). Pregabalin also signif-
icantly decreased the pain-related score at a dose of 10 mg/site.0 1 2 3 4
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Fig. 2. Effect of GT-0198 on glycine uptake via GlyT1 or GlyT2 in transfected human
embryonic kidney 293 cells. 100% inhibition means fully blocked by ORG24598 (3 mM)
and ORG25543 (100 nM) in GlyT1 and GlyT2 assay, respectively. Data are mean value of
representative experiments performed in duplicate.3.2. Antagonistic effect of strychnine on the analgesic effect of GT-
0198
To determine whether the action of GT-0198 was glycine- and
glycine receptor-mediated following inhibition of GlyT2, the
antagonistic effect of strychnine (a glycine receptor antagonist) on
the analgesic effect of GT-0198 was evaluated. The analgesic effect
of intravenous injection of GT-0198 was antagonized by intrathe-
cally administered strychnine in all experimental periods (Fig. 5).
Injection of strychnine alone in the spinal cord showed no effect on
the pain-related score (data not shown).
4. Discussion
In this study, we investigated whether GT-0198, a structurally
novel GlyT2 inhibitor that suppresses the uptake of glycine in hu-
man GlyT2-expressing HEK293 cells with submicromolar IC500 1 2 3
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Fig. 4. Effects of GT-0198 on pain-related behavioral responses to mechanical stimuli
in mice with partial sciatic nerve ligation. GT-0198, pregabalin, and vehicle were
injected intrathecally 7 days after nerve ligation. The hind paws were stimulated using
a von Frey ﬁlament with a bending force of 0.16 g. The values represent the mean and
S.E.M. of 4e6 animals. *P < 0.05 vs. vehicle-injection (Two-way ANOVA).
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Fig. 5. Effects of strychnine on analgesic-like effect of GT-0198. GT-0198 was injected
systemically; 15 min later, strychnine was injected intrathecally. At 0.5, 1, and 3 h after
the injection, the hind paws were stimulated using a von Frey ﬁlament with a bending
force of 0.16 g. The values represent the mean and S.E.M. of 3e6 animals. *P < 0.05 vs.
vehicle-injection (Two-way ANOVA).
Y. Omori et al. / Journal of Pharmacological Sciences 127 (2015) 377e381380values, has a potent analgesic effect on a mouse model of neuro-
pathic pain. Systemic (10 and 30 mg/kg; p.o.) and intrathecal (1, 10,
and 100 mg/site) injection of GT-0198 exhibited an analgesic effect.
The analgesic efﬁcacy of GT-0198 was almost the same as that of
pregabalin at a dose of 10 mg/kg by systemic injection or 100 mg/
site by intrathecal injection. GT-0198 did not inhibit GlyT1 and did
not bind to major receptors or transporters of neurotransmitters
such as GABA, serotonin, and glutamate (Table 2). Thus, we
considered that GT-0198 is a selective GlyT2 inhibitor and that its
analgesic effect occurs at least partly via inhibition of glycine up-
take in the spinal cord.
In previous studies, ALX1393 and ORG25543, typical GlyT2 in-
hibitors, showed analgesic effects against neuropathic pain and
mechanically, heat-, and formalin-induced acute pain (13,19,20).
However, these compounds showed minimal brain penetration.
The brain/plasma ratio is 0.0036 and 0.53 after intravenous injec-
tion of ALX1393 and ORG25593, respectively (20). On the other
hand, this ratio of GT-0198 is 16.7 after oral administration.
Therefore, GT-0198 bearing a phenoxymethylbenzamide moiety
has improved poor in vivo pharmacokinetics parameters property
of two published GlyT2 inhibitors.
Because oral administration of GT-0198 showed analgesic
properties, we propose that GT-0198 may be delivered as tablets or
capsules. Moreover, GT-0198 produced no side effects such as
convulsions, tremors, or even sedation ormotor disinhibition. Thus,
we expect GT-0198 to become an analgesic drug that can be used in
clinical practice.
GlyT2 is restricted to glycinergic synapse-rich regions in the
central nervous system, including the spinal cord (15, 21). Based on
this localization, GlyT2 is believed to function as a glycine reuptake
transporter at inhibitory glycinergic synapses (15, 22). In a previous
study, glycinergic transmission was increased by the pharmaco-
logical blockade of GlyT2 in lamina X neurons of rat spinal cord
slices (23). An increase in extracellular glycine concentrations was
also demonstrated by microdialysis perfusion of the dorsal spinal
cord of rats with the GlyT2 inhibitor ORG25543 (24). Taken
together, these ﬁndings suggest that the analgesic effect of intra-
thecal GT-0198 observed in the present study results from the
accumulation of glycine at the glycinergic synaptic cleft and sub-
sequent suppression of excitatory neuronal activities in the spinal
dorsal horn. In fact, glycinergic inhibitory postsynaptic currents
were markedly reduced in the motor neurons from GlyT2-deﬁcient
mice and the analgesic effect of the systemic injection of GT-0198
was abolished by the intrathecal injection of the glycine receptor
antagonist strychnine.
In this experiment, GT-0198, considered to be a GlyT2 inhibitor,
showed an analgesic effect on a mouse model of neuropathic pain.The analgesic effect of a GlyT2 inhibitor has been shown in not only
neuropathic pain but also another pain models. For example, N-
arachidonylglycine, known as a GlyT2 inhibitor (25), was effective
in suppressing phase 2 [acute inﬂammatory phase (26, 27)] of
formalin-induced pain behaviors (28) and also in an animal model
of complete Freund's adjuvant-induced inﬂammatory pain (13).
These results suggest that GlyT2 inhibitors are suitable as a thera-
peutic agent even for inﬂammatory pain. Moreover, intrathecal
injection of the GlyT2 inhibitor ALX1393 dose-dependently sup-
pressed dynamic allodynia in mice with herpetic and postherpetic
pain induced by percutaneous inoculation with herpes simplex
virus (HSV) type 1 (29). This model shows zoster-like lesions
throughout the inoculated dermatome (30e32), which may be
caused by proliferation of HSV in the dorsal root ganglion (30, 33).
These results suggest that GT-0198, considered to be a GlyT2 in-
hibitor, may alleviate pain symptoms that accompany neuropathic,
inﬂammatory, herpetic, and postherpetic pain.
The GlyT2 inhibitor ALX-1393 signiﬁcantly increased intercon-
traction interval and micturition pressure threshold in
cyclophosphamide-treated rats (34). These results indicate that
inhibition of GlyT2 leads to amelioration of cyclophosphamide-
induced bladder overactivity and that GT-0198 may be a drug for
the treatment of overactive bladder.
In summary, we have shown that GT-0198 had an analgesic ef-
fect in an animal model of neuropathic pain and suggest that GT-
0198 could reduce this pain by inhibiting spinal GlyT2. GT-0198 is
a structurally novel compound, with demonstrated analgesic efﬁ-
cacy in a behavioral model of neuropathic pain.Conﬂicts of interest
The authors have no conﬂict of interest directly relevant to the
content of this article.References
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